LMWH Use for VTE Prophylaxis in COVID-19 Hospitalized Patients – Multicenter Data from China
Thrombosis Journal posted on X:
”Real-world practices of low-molecular-weight heparin for venous thromboembolism prophylaxis in patients hospitalized with COVID-19: a multicenter prospective study from China.”
A multicenter prospective study in China (Dec 2022–Jan 2023) analyzed real-world use of low-molecular-weight heparin (LMWH) in 4,236 hospitalized COVID-19 patients.
Thromboprophylaxis practices varied widely, with many receiving reduced doses; dosing and duration were influenced by age, disease severity, renal function, platelet count, anemia, and concurrent antiviral or corticosteroid use.
Read the full article here.
Article: Real-world practices of low-molecular-weight heparin for venous thromboembolism prophylaxis in patients hospitalized with COVID-19: a multicenter prospective study from China
Authors: Feiya Xu, Yuzhi Tao, Lijun Chen, Yunhui Zhang, Binliang Wang, Jing Han, Chaosheng Deng, Weijia Liu, Guohui Fan, Rui Liang, Zhaofei Chen, Yinong Chen, Kaiyuan Zhen, Yunxia Zhang, Zhu Zhang, Shuai Zhang, Jun Wan, Wanmu Xie, Peiran Yang, YuTing Kang, Dingyi Wang, Chen Wang, Zhenguo Zhai
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia